Navigation Links
New Malaria Drug Proves Effective in Study of African Children
Date:11/7/2010

SATURDAY, Nov. 6 (HealthDay News) -- The death rate among children with severe malaria was nearly one-fourth lower when they received a new drug called artesunate than when they got the standard treatment of quinine, a new study shows.

The finding suggests that artesunate should replace quinine as the malaria treatment of choice for severe malaria worldwide, the researchers said.

Malaria, a disease that is transmitted via the bite of an infected mosquito, can quickly become life-threatening if left untreated, according to the World Health Organization.

The new study included 5,425 children with severe falciparum malaria -- the most dangerous of four types of malaria affecting humans -- in nine African countries. Of the children, 2,713 were treated with artesunate and 2,713 with quinine. There were 230 deaths (8.5 percent) in the artesunate group and 297 deaths (11 percent) in the quinine group, the study authors reported.

That means the risk of death was 22.5 percent lower for children who received artesunate. The investigators also found that side effects such as coma and convulsions were less frequent among those given artesunate.

The study authors, Nicholas White of Mahidol University in Bangkok, Thailand, and colleagues from the AQUAMAT study group, also noted that while artesunate is more expensive to buy, quinine is more expensive to administer.

"A major factor restricting the deployment of artesunate has been unavailability of a product satisfying international good manufacturing standards. The most widely used product, assessed in this study, does not yet have this certification, which has prevented deployment in some countries. This barrier must be overcome speedily so that parenteral artesunate can be deployed in malaria-endemic areas to save lives," White's team wrote in a news release.

The study, which was released online in advance of publication in an upcoming print issue of The Lancet, was scheduled for presentation Saturday at a meeting of the American Society for Tropical Medicine and Hygiene, held in Atlanta.

A previous study found that the malaria death rate among Southeast Asian adults treated with artesunate was 14 percent, compared with 23 percent for those treated with quinine. Following that study, the World Health Organization changed its guidelines to recommend artesunate for severe malaria in adults.

But this additional study was needed because it was thought the disease course could be different in African children.

"Artesunate should now become the treatment of choice for severe malaria for children and adults worldwide," the authors of the new study concluded.

"Malaria causes an estimated 800,000 deaths every year in African children. Severe malaria is often the most common admission diagnosis in febrile children, so a change in treatment policy from quinine to artesunate has the potential to save thousands of children's lives every year," White and colleagues stated in the news release.

"If 4 million African children with severe malaria every year were to receive prompt treatment with parenteral artesunate instead of quinine, and the benefits were similar to those recorded in this trial, then approximately 100,000 lives might be saved per year," they concluded.

More information

The U.S. Centers for Disease Control and Prevention has more about malaria.

-- Robert Preidt

SOURCE: The Lancet, news release, Nov. 6, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. MARA Fights Malaria With WaveMaker and Amazon Web Services
2. One-third of antimalarial medicines sampled in 3 African nations found to be substandard
3. Private Sector, President's Malaria Initiative Join Forces to Strengthen Angolas Capacity to Control Mosquitoes
4. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
5. Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria
6. Malaria research must be based in Africa
7. Invisible Children's Bobby Bailey Premiers a New Documentary on Malaria
8. High School Student's College Prerequisite: Save Five Thousand Lives in Africa. Teen Supports Nothing But Nets in Malaria Fight
9. SC Johnson and Bill & Melinda Gates Foundation Unite to Combat Malaria
10. Grassroots Campaign Drives toward Ending Malaria Deaths by 2015
11. Mosquito Squad Partners with Malaria No More
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Malaria Drug Proves Effective in Study of African Children
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: